Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
Ophthalmology
Jiangsu Hengrui Announces NMPA Approval for Miebo in Dry Eye Disease Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...
China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...
Santen’s Tapcom Administered to First Patient in GBA via Drug Access Policy
Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...
Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...
Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...
Santen’s Ryjunea Gets EU Approval to Slow Myopia Progression in Children
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from the European...
Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development
Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...
Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...
Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial
Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...
Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market
US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...
Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...
EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), the US partner of China-based Betta Pharmaceuticals (SHE: 300558), announced...
Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center
China-based Shenyang Xingqi Pharmaceutical Co., Ltd (SHE: 300573) announced plans for a private placement of...
Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment
Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...
StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...
Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...
Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals
German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency’s (EMA) Committee for...
Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...
NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment
China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...